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Abstract
Evidence-based medicine (EBM) is a fashionable and an extremely hot topic for clinicians, patients
and the health service planners. Evidence-based cytology (EBC) is an offshoot of EBM. The EBC is
concerned with generating a reproducible, high quality and clinically relevant test result in the field
of cytology. This is a rapidly evolving area with high practical importance. EBC is based entirely on
research data. The various professional bodies on cytology design and recommend guidelines on
the basis of evidences. Once the guideline is implemented and practiced then the experiences of
the practicing cytopathologists may be used as a feed back to alter the existing guideline. The
various facets of EBC are sampling and specimen adequacy, morphological identification and
computer based expert system, integrated reporting, identification of the controversial areas and
high quality researches for evidences. It is the duty of the individuals and institutions to practice
EBC for better diagnosis and management of the patients. In this present paper, the various aspects
of EBC have been discussed.
Background
Evidence-based medicine (EBM) is a fashionable and an
extremely hot topic for clinicians, patients and the health
service planners. EBM is defined as "the conscientious,
explicit and judicious use of current best evidence in mak-
ing decision about the care of individual patients [1]. Evi-
dence-based cytology (EBC) is an offshoot of EBM. The
EBC is concerned with generating a reproducible, high
quality and clinically relevant test result in the field of
cytology. This is a rapidly evolving area with high practical
importance. To the best of my knowledge, till now there
is no article on evidence based cytology in English litera-
ture. In this present paper I have discussed the various
aspects of EBC.
Increased demand for EBC
There is increased demand for EBC because of various rea-
sons. There is massive explosion of knowledge in the med-
ical science particularly in basic science. There are also
many newer technologies and diagnostic modalities in
hand. Therefore there is a need to integrate knowledge.
There is also a massive increase of health care costs and
overall workload. So it is necessary to make the best use of
finite financial resources. The general patients are now
more educated and have easier access to electronic media.
So, they demand the best quality diagnostic tests in mini-
mal period of time. Lastly there is increasing attention of
the medico-legal problems in cytology. Practicing EBC
may have some role in these areas.
EBC practice in clinical cytology laboratory
Figure 1 highlights the overall view of EBC. There is need
of good quality evidences in the field of cytology. These
evidences should be derived from high quality research
works. The basic data of cytology is handled by three
branches of science, 1) statistics 2) epidemiology and 3)
Published: 08 January 2007
CytoJournal 2007, 4:1 doi:10.1186/1742-6413-4-1
Received: 30 October 2006
Accepted: 08 January 2007
This article is available from: http://www.cytojournal.com/content/4/1/1
© 2007 Dey; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.CytoJournal 2007, 4:1 http://www.cytojournal.com/content/4/1/1
Page 2 of 9
(page number not for citation purposes)
informatics. The team of experts should meet together
periodically to make guidelines. These guidelines may be
considered as the founder pillars of EBC. Based on the
guidelines the EBC could be practiced.
Guidelines in EBC
There are various guidelines developed by different pro-
fessional bodies for practicing EBC [2-5]. The guidelines
may be opinion-based, consensus-based or evidence-
based. In opinion based guidelines, one or more experts
publish their recommendations which may or may not be
opposed by others. In consensus-based guidelines, a
group of experts meet and reach to a conclusive guideline.
This is relatively rapid, inexpensive method and there may
be potential bias in the recommendations [6,7]. Evidence-
based guideline is the most desirable one. This is based on
systematic identification, critical appraisal, and synthesis
of evidences. Ideally, all the recommendations should be
supported by enough evidences and the evidences should
be analyzed before making guidelines. The most impor-
tant or controversial questions should be dealt with great
attention and systematic review should be done on that
aspect. The method section of the guideline should be
clearly described by the guideline development group.
The member of a guideline development team should be
from expert in the field of particular branch of cytology,
clinicians, statistician, literature searcher and laboratory
manager. The key to successful recommendation of guide-
line depends on multidisciplinarity of the guideline devel-
opment team.
Overview of evidence-based cytology Figure 1
Overview of evidence-based cytology.
     Identify the questions 
Search for evidences from
              research data of cytology
  Statistics   Epidemiology  Informatics      Modify data 
   Best practice guidelines          Audit practice 
    Practice of EBC 
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A guideline should always be realistic so that its imple-
mentation is possible. Evidence based guideline contains
graded recommendation which is influenced by the
strength of evidence and clinical judgments. If a recom-
mendation is not supported by high grade evidence, then
it should be based on consensus of the members [8].
Seeking evidences for evidence based cytology
Booth et al [9] in a review on evidence based pathology
described the methods of evidence seeking techniques in
general. However, these could be applied in the field of
cytology. The first essential stage in evidence-seeking proc-
ess is formulating or focusing our question/s. This will
help us to use our search strategy on relevant database.
Such as the question may be asked as "what will be the
best re-screening method in conventional cervical cytol-
ogy smear?". We can translate this question into a search
strategy in the form of key words: "re-screening" AND
"method" AND "cervical cytology". If we get systematic
review or meta-analysis in the search result, then we can
concentrate on these.
We can start with MEDLINE data base as the primary
source followed by Cochrane Library and Health Technol-
ogy Assessment database of the NHS Centre for reviews
and dissemination.
Sampling and specimen adequacy, and EBC
Sampling and specimen adequacy in cytology is an impor-
tant aspect of EBC because the proper way of sample col-
lection has great impact on the test result. It is also
necessary to have adequate cells on the smear. There are
various guidelines on the sampling and specimen ade-
quacy by different expert committee [2-5,10,11] on respi-
ratory specimen, urine, thyroid, breast and cervical
smears. Table 1 highlights the necessary instructions
about the specimen collections in exfoliative cytology.
The sensitivity of sputum cytology increases when the
samples are obtained over five consecutive days [14,15].
However it has been noted that three consecutive speci-
mens of sputum samples has reasonable sensitivity for
detection of malignancies [16]. In microscopy, well pre-
served, well stained cytologic material with numerous
alveolar macrophages are essential for adequate sputum
[12]. Greenberg et al noted that adequacy of a sputum
sample is directly proportional to the number of alveolar
macrophages it contains [17]. Bronchial washings and
brushings are complementary to sputum cytology in the
diagnosis of respiratory tract lesions. The sample should
be obtained from clinically suspicious area by repetitive
installation of 3–5 ml sterile balanced salt solution
through the bronchoscope. In general a large number of
well preserved, optimally stained ciliated bronchial epi-
thelial cells and macrophages are necessary to have a sat-
isfactory specimen. However any specimen that contains
cells or agents diagnostic of a pathologic agent should be
considered as adequate [3]. The specimens which are
heavily contaminated and obscured by oral squamous
cells, blood, inflammatory cells or air drying artefacts
should be labeled as unsatisfactory [3].
A voided urine specimen can be collected in any conven-
ient time of the day, 3–4 hours after the patient last voided
and approximately 100–300 ml of urine should be col-
lected [2]. There is still no specific guidelines on the ade-
quacy of urine sample. Papanicolaou's society of
cytopathology practice guidelines task force believe that
further studies should be done on adequacy of urine sam-
ple [2].
Accurate cervical sampling with the help of correct device/
s is the most important part of an adequate cervical smear
[18,19]. Inadequate sampling and sample transfer to the
glass slides by the traditional or conventional method
probably the major cause of false negative cytology [20].
The cytologic sampling of the cervix is taken by different
people with different background. When sampling is
faulty, the other part of the exercise such as examination
and reporting on the specimen are in vain. The medical
staff must receive appropriate training in taking cervical
sampling. A close monitor of sample adequacy rate for
each smear taker and regular feed back may improve the
quality of the smear. In addition to properly collected
sample, a relevant clinical data from history, inspection
and palpation are also important.
The collection devices of cervical smear have great impact
on adequacy of the materials [18]. A meta-analysis study
showed that the widely used Ayre's spatula is the least
effective device for cervical sampling and gives a lower
yield of abnormal squamous cells [18]. Extended tip spat-
ula along with cytobrush is the best combination of cervi-
cal sampling devise for adequate smear [18].
The Bethesda System, 2001 (TBS) tried to develop a stand-
ard framework on evaluation of specimen adequacy and
reporting format [21]. According to TBS 2001, satisfactory
samples should have the presence of endocervical cells/
transformation zone (EC/TZ) component. There should
be at least 10 well preserved endocervical or metaplastic
squamous cells singly or in groups (table 2) [21]. The
assessment of the cellularity of the smears was also recon-
sidered in the meeting. The minimal squamous cellularity
was suggested as 8000 to 12000 well-visualized squamous
cells in conventional smears and 5000 squamous cells for
liquid based preparations [22]. It seems that the counting
of individual cells is clearly impractical. What may be the
rationality of the presence or absence of endocervical cells
related with sample adequacy? There are conflicting
reports on the presence of EC/TZ cells on cervical smearsCytoJournal 2007, 4:1 http://www.cytojournal.com/content/4/1/1
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and detection of squamous intraepithelial lesion (SIL)
[23-26]. However, many retrospective longitudinal stud-
ies have demonstrated that lack of EC/TZ cells on smears
do not have increase chance to develop SIL [7,25]. There
may be variable presence of endocervical cells in woman
who are pregnant, post menopausal or in oral contracep-
tives [28,29]. We should also remember that the identifi-
cation of EC/TZ cells is also subjected to inter-observer
variability [30]. Nevertheless, the regular feedback on EC/
TZ cells may have value in improving overall specimen
quality, and awareness of development and use of more
sensitive collection technologies. It is expected that the
changing incidence of cervical adenocarcinoma may alter
the implication of EC/TZ sampling [31]. It is also impor-
tant to note that other adequacy factors such as obscuring
blood or inflammation, and excessive cytolysis should be
evaluated in terms of their influence on sensitivity. Liquid
based preparations may markedly reduce blood, inflam-
mation or air drying effect along with less number of EC/
TZ cells [32]. The number of endocervical cells and
sqamous cells for adequacy in liquid based cytology are
still a questionable issue.
Criteria for determining adequacy of FNAC of thyroid
lesion is not settled till now and it varies from institution
to institution (table 3). Papanicolaou Society of Cytopa-
thology Task Forces on Standard of Practice has tried to
solve this issue [4] but ultimately did not specify any
numbers and groups of thyroid follicular epithelial cells
for specimen adequacy. One group of investigators sug-
gest that an adequate sample should contain five to six
groups of well-preserved, well-visualized follicular cells
with each group contains 10 or more cells [33]. Another
group has opinion that ten clusters of follicular cells with
at least 20 cells in each cluster are required to have ade-
quate sample [34]. Whereas other suggest that at least six
groups of follicular cells should be present on at least two
of six aspirates of Fine needle aspiration cytology (FNAC)
thyroid for considering adequate specimen [35]. The
Papanicolaou Society of Cytopathology Task Forces on
Standard of Practice admitted that the cellularity of a spec-
imen is greatly influenced by nature of the lesion. Many
cases of benign colloid goiter yield abundant colloid but
few follicular cells and should not be considered as inad-
equate.
Table 1: Sampling and specimen adequacy of exfoliative and gynaecologic sample
Sample Specimen collection Adequacy Diagnostic categorization Guideline society
Sputum Early morning 
spontaneously produced 
sputum. Three adequate 
single specimens. [12]
Well preserved, well 
stained cytologic material 
with numerous alveolar 
macrophages. [12]
1. Non-diagnostic
2. Specific benign lesion
3. Atypical cell present, 
probably benign
4. Atypical suspicious for 
malignancy
5. Malignancy
Papanicolaou's society 
guidelines, 1999 [3], [12]
Bronchial wash and brush Specimen from clinically 
suspicious area by 
repetitive installation of 3–
5 ml sterile balanced salt 
solution
A large number of well 
preserved, optimally 
stained ciliated bronchial 
epithelial cells and 
macrophages.
As above Papanicolaou's society 
guidelines, 1999 [3]
Voided urine sample Any convenient time, 3–4 
hours after the patient last 
voided. approximate 100–
300 ml
No definite number of cells 
mentioned. Probably a slide 
should contains at least 15 
well visualized basal and 
intermediate cells [13]
1. Negative
2. Infectious agents: 
bacterial, fungal, viral
3. Nonspecific 
inflammatory changes: 
acute inflammation, chronic 
inflammation, consistent 
with xanthogranulomatous 
pyelonephritis
4. Cellular changes 
associated with 
chemotherapeutic agents 
or radiation
5. Epithelial cell 
abnormalities: a) atypical 
urothelial cells, b) low 
grade urothelial carcinoma 
c) High grade urothelial 
carcinoma d) squamous cell 
carcinoma e) 
adenocarcinoma f) other 
malignancy
6. Other
Papanicolaou's society 
guidelines, 2003 [2]CytoJournal 2007, 4:1 http://www.cytojournal.com/content/4/1/1
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In September, 1996, the National Cancer Institute spon-
sored a conference to provide a uniform guideline to
FNAC of breast [5]. The controversial topic of adequacy of
breast FNA was discussed, but no specific comment was
made on requirement for a minimum number of ductal
cells for an adequate specimen. (Table 3). The task has
been transferred to the aspirator and reporting pathologist
to judge the adequacy of the specimen. This particular
issue has evoked much controversy in past [36,37]. Many
studies have highlighted that the false negative FNAC of
breast lesions have a low cellularity [36,38]. Therefore,
many authors feel that the sample having minimum
number of cells should be reported as non-diagnostic
[39,40].
Till now to best of my knowledge, no such guideline has
been set for FNAC of lymph node and other organs.
Identify and interpret: What is the role of expert 
system?
The tasks of cytopathologist are two folds: at first he
should sort out the representative cells or cells of interest
and second, he should objectively assess the morphologic
alteration of the cells. When the cytopathologist is chal-
lenged to detect occasional abnormal cells in the midst of
large number of normal cells, computer assisted screening
may be helpful. The three different automated screening
techniques were developed in the field of cervical cytol-
ogy. These are PAPNET, AutoPap and AutoCyte Screen
[41-46]. However, no such system is available commer-
cially for exfoliative cytology or FNAC smears.
Human perception and interpretation are considered
highly valuable in diagnostic interpretation. However it is
of no doubt that human assessment of cytology smears
and even histopathology sections are too some extent sub-
jective and have very low inter-observer's agreement and
low K value in certain situations [47-50]. Various compu-
ter based expert systems have been used for an objective
approach in diagnosis [51-56]. Expert systems are compu-
ter programs that can perform reasoning tasks and can be
used for diagnostic difficulties. These systems are based on
Bayesian belief network (BBN), artificial neural net
(ANN) works, and logistic regression analysis [51-56].
Bayesian belief networks (BBN) have been used by vari-
ous authors [51,52] to diagnose the cases of benign and
malignant lesions in FNAC of breast lesions. The ability of
the BBN was satisfactory in diagnosis decision making. It
was concluded that this expert system can help in consist-
ent and objective diagnosis of breast lesions.
Another group of researchers [53] investigated the poten-
tial of the ANN for the discrimination of benign from
malignant breast lesions. This neural network showed
excellent performance for correct classification of cells.
Table 2: Sampling and specimen adequacy of gynaecologic sample
Sample Specimen collection Adequacy Diagnostic categorization Guideline society
Cervical smear The whole cervix should 
be visualized and the whole 
TZ area should be sampled.
Cytobrush along with 
extended tip spatula is the 
best combination. (Lancet 
review).
Rotate the spatula through 
more than one complete 
turn. Immediately transfer 
the cells to the slides and 
immediately fix the smear 
by immersing in alcohol.
Satisfactory samples should 
have the presence of 
endocervical cells/
transformation zone 
component. There should 
be at least 10 well 
preserved endocervical or 
metaplastic squamous cells 
singly or in groups [22].
• Negative for 
intraepithelial lesion
• Epithelial cell 
abnormalities
Squamous cell
• Atypical squamous cells 
of undetermined 
significance (ASC-US) and 
can not exclude HSIL
• Low grade squamous 
intra epithelial lesion (LSIL)
• High grade squamous 
intra epithelial lesion 
(HSIL)
• Squamous cell carcinoma
Glandular cell
• Atypical glandular cells
• Atypical glandular cells 
favor neoplastic
• Endocervical 
adenocarcinoma in situ
• Adenocarcinoma
Other
• Endometrial cells in a 
woman > 40 years of age
The 2001 Bethesda System 
[22]CytoJournal 2007, 4:1 http://www.cytojournal.com/content/4/1/1
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The potential of back propagation neural networks in the
discrimination of benign from malignant thyroid lesions
were examined by Karakitsos P, et al [54]. It was con-
cluded that use of ANN may improve the diagnostic accu-
racy of FNA of the thyroid gland, especially in cases
classified as suspicious for malignancy.
The potential value of morphometry and ANN for dis-
criminating benign from malignant nuclei and lesions of
the lower urinary tract on images of routinely processed
voided urine smears were investigated by Karakitsos P et
al [55]. Application of ANN offered good classification at
the nuclear and patient level and promised to become a
powerful tool for everyday practice in the cytologic labo-
ratory.
Another group of researchers investigated the potential
value of morphometry and the back propagation neural
network for the discrimination of benign and malignant
lesions in images of routinely processed gastric smears
stained by the Papanicolaou technique [56]. Their results
indicate that ANN and image morphometry may offer
useful information about the potential for malignancy in
gastric cells.
This type of expert based system is valuable however the
professional societies of the pathologists and cytopathol-
ogists should take active participation in designing, evalu-
ating and modifying such systems.
Reporting
Reporting is one of the important components of genera-
tion of a test result. Optimum content and format of the
report are necessary for appropriate communication with
the clinicians and the patient. There are various guidelines
on the diagnostic entities in exfoliative and fine needle
aspiration cytology [2-5]. (table 1, 2, 3). Reporting for-
mats can be in the form of check list type i,e proforma
report or descriptive report or computer generated.
Pathologist should be extremely careful about the termi-
nology or phases to express the certainty. Certain phrases
such as "suggestive of", "consistent with", "possibly" etc.
should be carefully used. Indiscriminate use of the phrase
may generate confusion to the clinician [57].
Integrated approach of reporting
In recent days, there is massive advancement in the field
of molecular biology and computer technology. The mas-
sive explosion of knowledge has also significant impact
on cytologists. Along with cytomorphology of a lesion,
the cytologists now have the information of immunocyto-
chemistry, biochemical profiles and molecular details. So
a pan-diagnostic approach is needed [58], which will be
in other word a morpho-molecular approach to tissue
Table 3: Sampling and specimen adequacy of fine needle aspiration cytology sample
Sample Specimen collection Adequacy Diagnostic categorization Guideline society
Thyroid Multiple fine needle 
aspiration from different 
sites or fine needle 
sampling.
Different opinions
• Five to six groups of well-
preserved, well-visualized 
follicular cells with each 
group contains 10 or more 
cells. [33]
• Ten clusters of follicular 
cells with at least 20 cells in 
each cluster. [34]
• At least six groups of 
follicular cells should be 
present on at least two of 
six aspirates.[35]
• Unsatisfactory for 
interpretation, specific 
reason(s)
• Benign thyroid nodule/
colloid nodule/nodular 
goiter
• Thyroiditis
• Cellular follicular lesion, 
favor non-neoplastic 
process
• Follicular neoplasm, favor 
benign
• Follicular neoplasm, favor 
malignant
• Hurthle cell neoplasm
• Malignant specific type if 
possible
• Other
Papanicolaou's society 
guidelines, 1996 [4]
Breast Average 2–4 pass in 
palpable mass More than 2 
passes in lesion difficult to 
stabilize or penetrate, dry 
tap or in suspected 
carcinoma.
No consensus on number 
of cells in a solid breast 
lesion.
Adequacy determined by 
1) opinion of the aspirator 
2) opinion of the 
pathologist.
• Benign
• Atypical/indeterminate
• Suspicious/probably 
malignant
• Malignant: specific types
• Unsatisfactory Tumor/
nuclear grading should be 
incorporated in all breast 
carcinomas whenever 
possible.
NCI sponsored conference 
in Bethesda, Maryland 1996 
[5]CytoJournal 2007, 4:1 http://www.cytojournal.com/content/4/1/1
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diagnosis. The cytopathologist will have to combine the
clinical history of the disease with the cytomorphology,
immunocytochemical findings and molecular details for
precise diagnosis. In future, such "molecular cytopatholo-
gist" will play a central role in clinical decision making.
Role of open access article
Open access extends benefits of easy access for the readers
and wider real time dissemination of research areas in
cytology for the authors-researchers. Some of the benefits
of open access and comparison with conventional
method of publishing scientific knowledge are depicted in
a comic strip published previously [59]. The great benefits
of online open access journal are rapid turn around time,
real time publications and significant cost savings. The
open access journal helps in free flow of scientific infor-
mation which is immensely important for diagnosis and
management of diseases [59]. To avoid publication of
misguided substandard or faulty research, peer review of
every article is strongly favored [60]. Cytojournal is a peer
reviewed cytopathology journal which plays an important
role in publishing good quality research data in cytopa-
thology in open access [61]. The research articles are acces-
sible to any one from any part of the world independent
of the financial budget of the readers [62]. The online
nature allows interactive real time participation. The
reader can express their opinion immediately on any arti-
cle and this has definite positive impact on future of evi-
dence based cytology with wider participation.
Discussion and conclusion
EBC is based entirely on evidences which should be of
good quality. There are many publications which have
described how to generate bias free good quality evi-
dences from a research work [63-65]. The good quality
research studies can be produced by appropriate study
design of the work, explicit identification of the question,
appropriate choice of sample population, application of
ideal reference standard both to the test and control pop-
ulation, blind comparison of method against reference
and outcome, exclusion of confounding variables and
introducing reproducible methodology. The ultimate fate
of the research work is publication and there may be
potential bias in the publication of result because there is
greater chance of publication of positive findings [66].
This also should be avoided as far as possible.
The various professional bodies on cytology design and
recommend guidelines on the basis of evidences. We also
should keep in mind that there is no guarantee that these
guidelines will be followed by the practicing cytologists
[67]. It is the responsibilities of the individuals or institu-
tions to follow the most accepted guidelines. Once the
guideline is implemented and practiced then the experi-
ences of the practicing cytopathologists may be used as a
feed back to alter the existing guideline.
Systematic review is also very important in EBC. It is usu-
ally moderately comprehensive and summarizes all rele-
vant research information. It identifies various limitations
in methodologies of different studies and also helps to
limit bias. Systematic review helps to enhance confidence
in overall result and also reduces delay between discovery
and implementation of the knowledge. At the end it iden-
tifies new research questions [68]. However systematic
review may provide insufficient data. It is important to
find out that whether a comprehensive and explicit search
strategy has been used in the review or not? The quality of
the included studies in the review is also important.
The other aspect of the EBC is to employ computer based
expert system. This is in early stage of development. The
professional body of cytology can take part active role for
proper designing and application of these systems. Stand-
ard algorithm of reporting format may also help in diag-
nosis [69]. There should be large number of digital
pictures available in internet web pages for guidance of
diagnosis. Telepathology may also be helpful in diagnosis
of difficult cases.
The controversial areas of cytology should be identified
and multi-institutional, multinational high quality
research works should be done. The result of these
researches should be available to all. Open access journals
can play an important role for dissemination of knowl-
edge. In fact, there are many articles in Cytojournal on
thyroid FNAC, Anal pap, lymph node FNAC, urine cytol-
ogy, liver etc which probably bears good impact to the
cytopathology society [70-74].
It is of no doubt that the use of a diagnostic test is an inter-
vention [75] and the outcome of the cytologic test is part
of the decision making process that lead to an improved
outcome in clinical context. So we can say that a cytologic
test may improve the overall diagnostic process, therapeu-
tic strategy, and economic benefit. In fact it is an integral
part of evidence-based medicine. However, it is interest-
ing to note that evidence-based medicine appears to have
very little impact in the field of cytology. Probably it is
now the ideal time to integrate our information in more
productive way for better diagnosis and management of
the patients. This is the right time to practice evidence
based cytology.
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